Societal impacts of treatment of early breast cancer: implications for future research, policy and practice
Jun 11, 2019
RAND Europe conducted a study on the societal impact of early breast cancer, divided into three interconnected phases. The third phase was a qualitative study assessing the factors affecting access to and delivery of treatment for early breast cancer in a selection of countries, as well as a supra-national overview. This study is of interest to policymakers, healthcare professionals, patient advocates and others within the healthcare system.
Implications for future research, policy and practice
|PDF file||1.3 MB||
Use Adobe Acrobat Reader version 10 or higher for the best experience.
RAND Europe conducted a study on the societal impact of early breast cancer. This study was divided into three interconnected phases, which together aim to enrich the evidence base on the broader health, societal and economic impacts of treatment of early breast cancer, using a mixed methods approach. In the third phase of our programme we undertook a qualitative study using desk research and key informant interviews to explore the factors affecting access to and delivery of treatment for early breast cancer in order to identify what works and what can be improved. We focused on five countries (Brazil, Canada, Italy, Spain and the United Kingdom), and also present insights at a supranational level — for example policy and practice in the European Union — and make broader comments on factors affecting low and middle-income countries. We found that differences within countries are often related to regional discrepancies that arise from a decentralised structure of the healthcare system that has an impact on the financing, implementation, and/or delivery of care. We found that cultural and socioeconomic factors, such as a person's education or income, also affect equal access to treatment within an individual country. In all countries considered, breast cancer is a disease that benefits from strong patient advocacy, which has played an important role in raising the profile of breast cancer with patients, policymakers and the public, both at a national and international level. However, there is still little awareness of the impact of disease progression on society.
Interview consent form
The research described in this report was sponsored by F. Hoffmann-La Roche Ltd and conducted by RAND Europe.
This report is part of the RAND Corporation Research report series. RAND reports present research findings and objective analysis that address the challenges facing the public and private sectors. All RAND reports undergo rigorous peer review to ensure high standards for research quality and objectivity.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.